OncoMatch/Clinical Trials/NCT06906341
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Is NCT06906341 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Relacorilant 150 mg once daily (QD) and Nab-paclitaxel 80 mg/m^2 for ovarian cancer.
Treatment: Relacorilant 150 mg once daily (QD) · Nab-paclitaxel 80 mg/m^2 · Bevacizumab 10 mg/kg — This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Endometrial Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anticancer therapy
1 to 3 lines of prior systemic anticancer therapy
Must have received: systemic anticancer therapy — endometrial cancer
1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
Must have received: platinum-based chemotherapy — endometrial cancer
Prior treatment with a platinum agent
Must have received: anti-PD-L1 therapy — endometrial cancer
Prior treatment with an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
Cannot have received: relacorilant
Prior enrollment in a clinical trial of relacorilant
Cannot have received: weekly paclitaxel or nab-paclitaxel (paclitaxel, nab-paclitaxel)
Has progressed while receiving weekly paclitaxel or nab-paclitaxel
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- 150 · Palo Alto, California
- 014 · San Francisco, California
- 544 · Fort Myers, Florida
- 543 · West Palm Beach, Florida
- 518 · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify